Skip to main content
Premium Trial:

Request an Annual Quote

AI Digital Pathology Software Firm Proscia Receives CE Mark

NEW YORK – Proscia said today that it has received the CE mark for its Concentriq Dx digital pathology software for use in primary diagnosis.

Concentriq Dx enables pathologists to make a primary diagnosis of cancers and other diseases from digitized images of patients' tissue biopsies, helping laboratories to deliver more timely, high-quality diagnoses, Proscia said.

Receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally to help laboratories keep pace with the rising cancer burden, the firm said.

Proscia CEO David West said in a statement that challenges pathologists face in Europe "are reflective of global trends and highlight the need to accelerate diagnostic workflows and improve accuracy. Concentriq Dx can drive costs out of the health system, relieve overburdened pathology laboratories, and, most importantly, quickly get accurate answers to physicians and their patients."

The Philadelphia-based firm said that by centering the practice of pathology around images instead of physical glass slides, its software automates time-consuming and error-prone manual tasks, and streamlines access to specialized expertise.